Home / Health / Obesity Drug Trial Sees High Dropouts Over Side Effects
Obesity Drug Trial Sees High Dropouts Over Side Effects
1 Oct
Summary
- Nearly one in five patients left the survodutide trial.
- Gastrointestinal issues were the primary cause of dropouts.
- Drugmaker's shares fell sharply following the trial data release.
A significant number of patients are discontinuing their participation in Zealand Pharma's late-stage trial for the obesity drug survodutide. Data released on October 1, 2026, indicated that nearly one in five participants have withdrawn from the study. The primary reason cited for these departures is the occurrence of gastrointestinal side effects.
This development has triggered renewed investor apprehension, mirroring a similar situation in June. At that time, data from other late-stage survodutide studies revealed that approximately a quarter of patients had dropped out due to adverse effects. The recent disclosure has led to a notable decline in Zealand Pharma's share price, reflecting ongoing concerns about the drug's tolerability and potential impact on its market success. The drug is being developed in collaboration with Boehringer Ingelheim.
